Bachem Holding AG Asset Resilience Ratio
Bachem Holding AG asset resilience ratio. Bachem Holding AG (BANB) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Bachem Holding AG total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Bachem Holding AG (2005–2024)
Asset resilience ratio of Bachem Holding AG from 2005 to 2024. This chart shows how Bachem Holding AG's Asset Resilience Ratio has changed over time. See Bachem Holding AG free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Bachem Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Bachem Holding AG's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF0.00 | 0% |
| Total Liquid Assets | CHF0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Bachem Holding AG maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Bachem Holding AG Industry Peers by Asset Resilience Ratio
Compare Bachem Holding AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.57% |
|
Eupraxia Pharmaceuticals Inc
TO:EPRX |
Biotechnology | 25.13% |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089 |
Biotechnology | 3.60% |
Bachem Holding AG Asset Resilience Ratio by Year (2005–2024)
Bachem Holding AG asset resilience ratio by year from 2005 to 2024. The table below shows the annual Asset Resilience Ratio data for Bachem Holding AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | CHF0.00 ≈ $0.00 |
CHF1.92 Billion ≈ $2.43 Billion |
-- |
| 2023-12-31 | 8.37% | CHF140.80 Million ≈ $178.01 Million |
CHF1.68 Billion ≈ $2.13 Billion |
-8.76pp |
| 2022-12-31 | 17.12% | CHF236.98 Million ≈ $299.60 Million |
CHF1.38 Billion ≈ $1.75 Billion |
-10.07pp |
| 2021-12-31 | 27.20% | CHF353.17 Million ≈ $446.50 Million |
CHF1.30 Billion ≈ $1.64 Billion |
+26.80pp |
| 2013-12-31 | 0.40% | CHF1.73 Million ≈ $2.19 Million |
CHF438.78 Million ≈ $554.73 Million |
-0.26pp |
| 2008-12-31 | 0.66% | CHF3.01 Million ≈ $3.80 Million |
CHF457.32 Million ≈ $578.17 Million |
-2.46pp |
| 2007-12-31 | 3.12% | CHF13.39 Million ≈ $16.93 Million |
CHF429.07 Million ≈ $542.46 Million |
-9.59pp |
| 2006-12-31 | 12.71% | CHF56.20 Million ≈ $71.05 Million |
CHF442.24 Million ≈ $559.10 Million |
+1.03pp |
| 2005-12-31 | 11.68% | CHF47.69 Million ≈ $60.29 Million |
CHF408.21 Million ≈ $516.09 Million |
-- |
About Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commerci… Read more